Table 2.
Broth microdilution susceptibilities and MIC distributions for all 107 single-patient A. baumannii-calcoaceticus complex isolates and for isolates by the presence or absence of the blaOXA-23-like gene
| Agent | Result for isolatesa: |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total |
With the blaOXA-23-like gene |
Without the blaOXA-23-like gene |
|||||||
| MIC (μg/ml) |
% S | MIC (μg/ml) |
% S | MIC (μg/ml) |
% S | ||||
| 50% | 90% | 50% | 90% | 50% | 90% | ||||
| Imipenem | ≥16 | ≥16 | 37.4 | ≥16 | ≥16 | 0 | 4 | ≥16 | 78.4 |
| Meropenem | ≥16 | ≥16 | 35.5 | ≥16 | ≥16 | 0 | 4 | ≥16 | 72.5 |
| Doripenemb | ≥16 | ≥16 | 3.7 | ≥16 | ≥16 | 0 | 4 | ≥16 | 3.7 |
Among the total number of isolates, 56 (52.3%) had the blaOXA-23-like gene and 51 (47.7%) lacked it. S, susceptible.
FDA breakpoints were applied (≤1 μg/ml).